• LAST PRICE
    10.7900
  • TODAY'S CHANGE (%)
    Trending Down-0.2950 (-2.6613%)
  • Bid / Lots
    10.7900/ 4
  • Ask / Lots
    10.8100/ 1
  • Open / Previous Close
    10.8000 / 11.0850
  • Day Range
    Low 10.6900
    High 11.3700
  • 52 Week Range
    Low 1.2800
    High 16.2400
  • Volume
    506,758
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 11.085
TimeVolumeNKTX
09:32 ET3007011.01
09:34 ET557610.845
09:36 ET369710.8454
09:38 ET69610.87
09:39 ET378810.7912
09:41 ET35510.8
09:43 ET322610.82
09:45 ET67610.78
09:48 ET353510.815
09:50 ET763310.82
09:52 ET216410.845
09:54 ET1634910.98
09:56 ET405010.96
09:57 ET232411.04
09:59 ET108010.97
10:01 ET122310.97
10:03 ET216010.9891
10:06 ET290610.95
10:08 ET674910.8928
10:10 ET103210.82
10:12 ET373410.855
10:14 ET50010.8889
10:15 ET201810.96
10:17 ET473911.04
10:19 ET21611.08
10:21 ET302511
10:24 ET581711.06
10:26 ET50011.01
10:28 ET42011.0427
10:30 ET22211.005
10:32 ET201910.98
10:33 ET50010.99
10:35 ET279411.0004
10:37 ET185010.98
10:39 ET200910.995
10:42 ET33111.025
10:44 ET139711
10:46 ET244811.0226
10:48 ET24011.02
10:50 ET247811.055
10:51 ET81611.11
10:53 ET265811.17
10:55 ET504711.12
10:57 ET80411.14
11:00 ET80011.1
11:02 ET148911.08
11:04 ET1089911.24
11:06 ET227911.2696
11:08 ET232911.257
11:09 ET75011.265
11:11 ET424211.31
11:13 ET138611.34
11:15 ET515011.33
11:18 ET428111.31
11:20 ET70011.3039
11:22 ET140011.265
11:24 ET218811.27
11:26 ET10011.265
11:27 ET170711.25
11:29 ET134211.23
11:31 ET160311.13
11:33 ET50011.14
11:36 ET275111.12
11:38 ET76011.1
11:40 ET37511.1
11:42 ET636511.149
11:44 ET328311.13
11:45 ET172811.1
11:47 ET66511.1
11:49 ET110011.11
11:51 ET49511.09
11:54 ET300011.08
11:56 ET430411.02
11:58 ET190011.005
12:00 ET346910.9419
12:02 ET556311.0105
12:03 ET203211.025
12:05 ET193911.005
12:07 ET197510.92
12:09 ET200510.93
12:14 ET1335110.965
12:16 ET226410.94
12:18 ET129710.93
12:20 ET65010.88
12:21 ET525210.86
12:23 ET57410.87
12:25 ET170010.9
12:27 ET50510.8903
12:30 ET320510.884
12:32 ET304510.86
12:34 ET168010.82
12:36 ET460010.79
12:38 ET130010.8
12:39 ET20010.79
12:41 ET2935210.69
12:43 ET373810.74
12:45 ET293910.7323
12:48 ET360610.805
12:50 ET319010.82
12:52 ET10010.815
12:54 ET136310.83
12:56 ET70010.85
12:57 ET80010.82
12:59 ET271010.82
01:01 ET331810.82
01:03 ET10010.83
01:06 ET300810.85
01:08 ET232210.82
01:10 ET139010.83
01:12 ET150010.8
01:14 ET60010.8
01:15 ET160010.815
01:17 ET100010.815
01:21 ET180010.81
01:24 ET215010.8
01:26 ET1620010.8
01:28 ET244610.8
01:30 ET182510.8
01:32 ET207510.8
01:33 ET282110.83
01:35 ET202610.79
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNKTX
Nkarta Inc
778.1M
-4.5x
---
United StatesHLVX
Hillevax Inc
776.3M
-5.2x
---
United StatesCGEM
Cullinan Oncology Inc
763.6M
-4.7x
---
United StatesAVTE
Aerovate Therapeutics Inc
794.1M
-9.5x
---
United StatesPRAX
Praxis Precision Medicines Inc
783.7M
-2.5x
---
United StatesLBPH
Longboard Pharmaceuticals Inc
755.6M
-9.0x
---
As of 2024-03-28

Company Information

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.

Contact Information

Headquarters
1150 Veterans BoulevardSOUTH SAN FRANCISCO, CA, United States 94080
Phone
925-407-1049
Fax
302-655-5049

Executives

Independent Chairman of the Board
Ali Behbahani
President, Chief Executive Officer, Director
Paul Hastings
Chief Financial and Business Officer
Alyssa Levin
Chief Technical Officer
Ralph Brandenberger
Chief Scientific Officer
James Trager

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$778.1M
Revenue (TTM)
$0.00
Shares Outstanding
70.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.72
EPS
$-2.40
Book Value
$5.56
P/E Ratio
-4.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.